Apremilast treatment showed a trend toward reduced lipid droplet accumulation in both GAN and CHOW groups, although this did not reach statistical significance, suggesting a potential role of PDE4 inhibition in improving hepatocellular lipid handling.
← all excerpts
Apremilast attenuates hepatic steatosis and metabolic dysfunction in a murine model of MASLD: Implications for patients with Psoriatic disease.
1
—
—